Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.

Clinical trials sponsored by Shanghai Mabgen Biopharmaceutical Technology Co., Ltd., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug MG2512 enters human trials for Hard-to-Treat cancers Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

New drug MG2512 enters human trials for Hard-to-Treat cancers

Disease control Recruiting now

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

Phase 1 • Sponsor: Shanghai Mabgen Biopharmaceutical Technology Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC